Genomic Determinants of Response to Iberdomide Combination and Monotherapy in Early Relapsed Multiple Myeloma (IMS 2026) - Sep 11, 2026 - Abstract #PA-213; Pres time: Sep 24, 2026; "Introduction: Most patients with multiple myeloma (MM) develop lenalidomide (Len) resistance at first relapse. Most will receive a second IMiD (e.g., pomalidomide; Pom) during their course...We performed whole genome sequencing (WGS) for patients on the ReKInDLE study of Iberdomide, Carfilzomib, Daratumumab, and dex (Iber-DKd; n=32) for Len-exposed early-relapsed MM, with de-escalation to Iber monotherapy after 8 cycles... CELMoDs have activity in IMiD-resistant settings but discrete resistance variants apart from CRBN mutations appear to influence response, arguing for screening in IMiD-resistant scenarios, and for earlier CELMoD integration prior to selection of universal IMiD/CELMoD resistance. Sequencing of additional cases is in progress."
Monotherapy • Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • CRBN • DDB1 • IKZF1 • IL17RB • SDC1
|
|
Ola Landgren1,2; Abhishek Pandey1; Michael Durante1; Hsuan-Ting Huang1; Marios Papadimitriou1; Chrissy Baker1; Andrew Kowalski1; Leslie Gallardo1; David Coffey1; Brian Walker3; Rafat Abonour1; Gil Hevroni1; Daniel Bilbao1; Sion Williams1; Tomas Jelinek4; Dickran Kazandjian1; James Hoffman1; Benjamin Diamond1
|